Long-term safety and effectiveness of natalizumab treatment in clinical practice
Natalizumab treatment of multiple sclerosis – a Danish nationwide study with 13 years of follow-up
Long-term Safety and Effectiveness in Relapsing-Remitting Multiple Sclerosis over 15 Years
Natalizumab reduces loss of gray matter and thalamic volume in patient with relapsing remitting
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain
Do you have any queries or comments?
© 2024 Acino EduDoc – Medical education platform for HCPs in South Africa. All Rights Reserved.
This site contains general information on products which is targeted to a wide range of audiences in the African market. It may include product details or information that is unavailable or inapplicable in your country. Please be aware that we do not take any responsibility relating to access to such content. More information may be available from local regulatory authorities. For medical advice, please always consult a healthcare professional.
